Biopharma

As industry specialists, our bankers have extensive knowledge of your sector and the competitive landscape.

The rapid and cost-effective development of innovative therapeutics and treatments is critical not just to public health, but to the functioning of society and economic activity. Leading drug developers, as well as their partners across the research, development, and manufacturing value chain, count on our deep expertise in biopharma’s capital-raising and deal-making landscape.

We serve clients that operate across a broad range of therapeutic areas, including oncology, immunology, neurology, rare disease, genetic medicines, liver disease, and other specialty pharma areas.

Featured Successes

$168,000,000

Initial Public Offering

$269,747,100

has merged with

$209,299,994

Initial Public Offering

$306,681,983

Initial Public Offering

$143,750,000

Initial Public Offering

$45,499,905

PIPE

$63,250,000

Follow-on Offering

$516,000,000

has been acquired by

$539,000,000

has been acquired by

Not Disclosed

has been acquired by

For More Information

Please contact a member of the biopharma investment banking team.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures